title: Impaired endothelium-mediated vasodilation in heart failure: clinical evidence and the potential for therapy.
abstract: Numerous studies in the last decade have clearly shown an attenuated endothelium-dependent vasodilation in patients with chronic heart failure. This abnormality has been demonstrated in the peripheral, pulmonary, and coronary circulation in patients with both ischemic and nonischemic cardiomyopathy; its magnitude correlates with the severity of symptoms. Endothelial dysfunction in patients with cardiomyopathy and a relatively new onset of symptoms suggests that change in endothelial function occurs early in the course of the disease. In contrast to other circulatory beds, renal circulation has shown significant vasodilatory response to endothelial stimulation. The development of endothelial dysfunction may not be homogeneous, and its magnitude may differ among circulatory systems. Although the clinical implications of the attenuated endothelium-dependent vasodilation in heart failure are not clear, this condition may lead to decreased organ perfusion, impaired exercise tolerance, and progression of disease. Many therapeutic interventions have resulted in improvement of endothelial function in patients with heart failure. Some of these interventions have also proven effective in enhancing exercise capacity, symptoms, and survival in patients with heart failure. This association suggests a therapeutic role for improvement of endothelial function in patients with chronic heart failure.
authors.affiliation: Heart Failure Program, Division of Cardiology, Department of Medicine, University of Southern California School of Medicine, Los Angeles, CA 90033, USA.
authors.forename: Uri
authors.initials: U
authors.lastname: Elkayam
authors.forename: Salman
authors.initials: S
authors.lastname: Khan
authors.forename: Ather
authors.initials: A
authors.lastname: Mehboob
authors.forename: Nusrat
authors.initials: N
authors.lastname: Ahsan
mesh_terms: D004730:Endothelium, Vascular / Q000503:physiopathology*; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D009569:Nitric Oxide / Q000502:physiology; D013148:Spironolactone / Q000627:therapeutic use; D014664:Vasodilation / Q000502:physiology*
chemical_list: D013148:Spironolactone; D009569:Nitric Oxide